Home/Crossfire Oncology/Erik Ensing

EE

Erik Ensing

CBO

Crossfire Oncology

Therapeutic Areas

Crossfire Oncology Pipeline

Drug	Indication	Phase
CFON-026	B-cell malignancies (via BTK inhibition)	Pre-clinical
BAL0891	Oncology (via TTK/PLK1 inhibition)	Clinical (Phase not specified)

Leadership Team at Crossfire Oncology

Rogier Buijsman

Head of Chemistry

View full Crossfire Oncology profile